HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jason Isaacson Selected Research

2- (1- (2- (2,3- dihydro- 1- benzofuran- 5- yl)ethyl)piperidin- 3- yl)- 2,2- diphenylacetamide

10/2007Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jason Isaacson Research Topics

Disease

1Colorectal Neoplasms (Colorectal Cancer)
11/2014
1Neoplasms (Cancer)
11/2014
1Vesicular Stomatitis
10/2007
1Infections
10/2007

Drug/Important Bio-Agent (IBA)

1Sirolimus (Rapamycin)FDA Link
11/2014
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2014
1Pharmaceutical PreparationsIBA
11/2014
1dacomitinibIBA
11/2014
12- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA
11/2014
1Phosphotransferases (Kinase)IBA
11/2014
1Transcription Factors (Transcription Factor)IBA
11/2014
1Glycoproteins (Glycoprotein)IBA
10/2007
12- (1- (2- (2,3- dihydro- 1- benzofuran- 5- yl)ethyl)piperidin- 3- yl)- 2,2- diphenylacetamideIBA
10/2007

Therapy/Procedure

1Therapeutics
11/2014